



SPAFID
CONNECT

Informazione Regolamentata n. 0957-20-2022	Data/Ora Ricezione 13 Aprile 2022 16:41:55	Euronext Milan
--	---	----------------

Societa' : DiaSorin

Identificativo : 160391

Informazione
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 13 Aprile 2022 16:41:55

Data/Ora Inizio : 13 Aprile 2022 16:41:56

Diffusione presunta

Oggetto : Publication of the updated proxy forms for
voting through the Designated
Representative

Testo del comunicato

Please see the attachment.



The Diagnostic Specialist

PRESS RELEASE ○○○

DIASORIN: PUBLICATION OF THE UPDATED PROXY FORMS FOR VOTING THROUGH THE DESIGNATED REPRESENTATIVE

Saluggia, April 13, 2022 – With reference to the Shareholders' meeting called on April 29 2022 in a single calling, DiaSorin (FTSE MIB: DIA) announces that the proxy forms for voting through the Designated Representative, updated in the light of the proposals for resolution filed by the shareholder IP Investimenti e Partecipazioni S.r.l., are available to the public on the Company's website (www.diasoringroup.com, section "Governance"/ "Shareholders meetings"/"2022") and on the authorized storage mechanism used by the Company available on the website www.emarketstorage.com.

For additional information, please contact:

Riccardo Fava*Corporate Vice President Communication & Investor Relations*

Tel: +39.0161.487988

riccardo.fava@diasorin.it**About DiaSorin****Emanuela Salvini***Investor Relator*

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com

Fine Comunicato n.0957-20

Numero di Pagine: 3